30 , 31 It has been previously reported that platinum-based chemotherapeutic agents such as carboplatin increase intracellular ROS production, thereby triggering lipid peroxidation (as indicated by elevated MDA levels), inflammatory responses (increased TNF- and IL-6), cellular damage, and apoptosis
In a previous proteomics study, GPX4 was identified as a protein associated with neuromelanin in human brain [24]
[6] In other words, for most of your insulin response to food, it's not just the pancreas doing the work it's the pancreas getting a strong assist from a hormone your gut released
So those other medicines need to be tapered, at least while youre starting the GLP-1
How do the potential benefits of GLP-1 agonists in reducing risks of heart and kidney disease compare with the risks of side effects like hypoglycemia or gallbladder disorders, and how should a clinician balance these considerations